CORRECTED: Teva to Buy Migraine Treatment Co. in $825M Deal
Teva Pharmaceutical Industries Ltd. is acquiring privately held migraine-treatment company Labrys Biologics Inc. in a deal valued at up to $825 million in cash and contingent payments, the companies said Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article